GEM 21S
Commercial- Indications
- Periodontal defects, Bone regeneration, Gingival recession
Company intelligence / Profile preview
Lynch Biologics
Franklin, Tennessee, United Stateslynchbiologics.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Lynch Biologics provides GEM 21S®, a commercially available growth-factor enhanced matrix product for oral regenerative surgery that promotes rapid healing and new bone formation.
- Therapeutic areas
- OtherEndocrinologyInfectious Diseases
- Modalities
- Growth factorsBioactive proteins
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Lynch Biologics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lynch Biologics.